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Abstract
Background: Orphan drugs are a growing issue of importance to European healthcare policy makers. The success
of orphan drug legislation in Europe has resulted in an increasing number of licensed medicines for rare diseases,
and many more yet unlicensed products have received orphan drug designation. Increasingly the concerns
amongst policy makers relate to issues of patient access and affordability, yet few studies have sought to estimate
the future budget impact of orphan drugs. The aim of this study was to predict the total cost of orphan medicines
in Europe between 2010 and 2020 as a percentage of total European pharmaceutical expenditure.
Methods: A disease-based epidemiological model was created based upon trends in the designation and approval
of new orphan medicines, prevalence estimates for orphan diseases, and historical price and sales data for orphan
drugs in Europe (defined as Eurozone + UK). The analysis incorporated two stages:
1) Predicting the number of diseases for which new orphan drugs will be approved over the next decade, based
on an analysis of trends from the EU registry of orphan medicines;
2) Estimating the average ex-factory drug cost across an orphan disease life cycle, from the year in which the first
orphan medicine is launched to the point where the first medicine loses marketing exclusivity.
The two sets of information were combined to quantify the annual cost of orphan drugs from 2010 through 2020.
Results: The results from the model predicted a steady increase in the cumulative number of diseases for which
an orphan drug is approved, averaging just over 5 new diseases per year over the next 10 years. The annual per
patient cost of existing orphan drugs was seen to vary between €1,251 and €407,631, with the median cost being
€32,242 per year. The share of the total pharmaceutical market represented by orphan drugs is predicted to
increase from 3.3% in 2010 to a peak of 4.6% in 2016 after which it is expected to level off through 2020, as
growth falls into line with that in the wider pharmaceutical market. In sensitivity analysis peak-year orphan drug
budget impact ranged between 3% - 6.6%.
Conclusions: Although European orphan drug legislation has led to an increase in the number of approved
orphan drugs, the growth in cost, as a proportion of total pharmaceutical expenditure, is likely to plateau over the
next decade as orphan growth rates converge on those in the broader pharmaceutical market. Given the
assumptions and simplifications inherent in such a projection, there is uncertainty around the base case forecast
and further research is needed to monitor how trends develop. However, fears that growth in orphan drug
expenditure will lead to unsustainable cost escalation do not appear to be justified. Furthermore, based on the
results of this budget impact forecast, the European orphan drug legislation is not leading to a disproportionate
impact on pharmaceutical expenditure.
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Orphan diseases are rare and often debilitating conditions,
defined in the European Union (EU) as having a preva-
lence of no more than five per 10,000 people [1]. There
are believed to be between 5,000 and 8,000 different rare
diseases affecting an estimated 29 million people in the
EU [2]. Orphan drugs are those medicines used in the
diagnosis, prevention or treatment of orphan diseases.
European legislation passed in 2000 explicitly recognized
the unmet need of targeted treatments for orphan diseases
and created regulatory pathways and incentives for manu-
facturers to develop orphan drugs [3]. This regulation is
widely perceived to have been a success. From April 2000,
when the EU orphan drug regulation came into effect,
until October 2010, 720 drugs had received orphan drug
designation from the European Medicines Agency (EMA)
[4]. Of those designated drugs, 63 had been granted Mar-
keting Authorisation (MA), although some drugs had
obtained orphan drug designation and MA for more than
one indication (for example, imatinib received its initial
MA for chronic myeloid leukemia in 2001, and then
further approvals for additional orphan indications at later
time points).
While orphan drug designation and MA are EU centra-
lised procedures, decisions on pricing, reimbursement and
funding for orphan medicines remain the responsibilities
of Member States. This has led to uneven access to orphan
medicines across Europe [5]. Increasingly, issues of orphan
drug funding and access to medicines are becoming the
focus of discussion amongst health policy makers at a
European, country and local level. Concerns about the
cost of orphan medicines, at a per-patient level and in
aggregate, are delaying the acceptance and uptake of these
medicines [6]. Policy makers and healthcare managers are
concerned that, if left unmonitored, the future growth in
orphan drug cost will be prohibitive, and some have ques-
tioned whether the orphan drug regulation needs to be
revised [7,8].
Yet there is little published evidence upon which to
assess the current or future budget impact of orphan
medicines in Europe. Those studies that have attempted
to estimate budget impact are described below in chron-
ological order by the year of the budget impact estimate.
An analysis conducted in 2004 on behalf of the European
Commission predicted the future budget impact of orphan
drugs based upon the uptake of products that had been
introduced since the legislation was enacted in 2000 [9].
The researchers mapped the prices and accessibility of
orphan drugs in Europe, using a range of data sources.
Results showed that orphan drugs (those with orphan drug
designation) accounted for between 0.7 and 1.0% of phar-
maceutical expenditure in 2004 in France and Netherlands,
and predicted this would rise to between 6 - 8% by 2010.
It is noteworthy that this study was performed in 2004,
when limited knowledge on the trends of orphan drugs in
Europe was available.
A research thesis compiled by a Dutch student used data
from published literature and interviews to investigate the
cost of orphan drugs in the Netherlands. The study esti-
mated that the budget impact for orphan drugs reim-
bursed for use outside of hospital (‘extramural’)a c c o u n t e d
for 0.48% of the total Dutch drug expenditure in 2006
[10]. The author stated that extramural orphan drugs
represented 68% of all orphan medicines expenditure in
the Netherlands, suggesting that the total budget impact
of orphan medicines would have been approximately
0.75% of total pharmaceutical spend in 2006.
Orofino et al [11] performed a retrospective, cross-
sectional study on 38 orphan drugs in France, Germany,
Italy, Spain and the UK to determine the overall cost of
orphan drugs per country, compared to the total drugs
spend in 2007. Published disease prevelance data was
combined with IMS Health drug prices and manufacturer
information on recommended annual dosage for all
licensed orphan medicines. The authors found that the
average budget impact of orphan medicines accounted for
1.7% of the total drugs expenditure across the five
countries.
An analysis conducted by the Belgian Federal Centre for
Healthcare (KCE) [12] calculated the budget impact of
orphan drugs as a percentage of the total Belgian drug
budget in 2008, and then forecast the impact through
2013. By using three different scenarios reflecting different
levels of growth in orphan drugs in the EU, the number of
drugs reimbursed in Belgium, and the average annual cost
per patient, the authors estimated that orphan medicines
accounted for 1.9% of total pharmaceutical expenditure in
2008, and predicted it to grow to approximately 4% in
2013.
The most recent estimate of orphan drug budget
impact comes from Germany, where according to the
‘Arzneiverordnungsreport’ (Prescription drugs report),
orphan drugs accounted for 2.5% of Statutory Health
Insurance spending on drugs in 2009 [13].
The aim of this study was to estimate the European
budget impact of orphan medicines as a percentage of
total pharmaceutical expenditure, between 2010 and
2020, based upon 10 years of orphan drug experience in
Europe.
Methods
For the purposes of this study Europe was defined as the
Eurozone countries (AT, BE, CY, DE, EE, ES, FI, FR, GR,
IE, IT, LU, MT, NE, PT, SK, SL) plus the UK. These mar-
kets were considered to be more homogenous in their
approach to the provision of orphan medicines than the
broader EU-27 countries, where large disparities in access
to orphan medicines have been observed [5].
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medicines that have orphan drug designation. It did not
account for drugs that are used to treat rare diseases but
which were licensed prior to the introduction of the new
legislation in 2000, nor those for which the manufac-
turers did not seek orphan drug status. This approach is
in accordance with the previous studies in this area and
reflects the primary concern of healthcare providers,
which is the cost of new medicines launched on the back
of the 2000 orphan drug legislation [11,12].
A disease-based epidemiological modeling approach
was utilised to predict the future budget impact of
orphan drugs based upon historical trends and epidemio-
logical data. The primary unit of measurement in the
model is the orphan disease, rather than the orphan
drug. For any given year in the model, the total cost of
orphan drugs is estimated according to the number of
orphan diseases multiplied by the average orphan disease
medicine cost.
Predicting the number of orphan diseases
For costing purposes in the model, an orphan disease was
defined as a condition for which at least one orphan
medicine is licensed; an orphan disease came into exis-
tence in the model during the year in which the first
medicine designated for that condition was licensed. By
using the orphan disease, rather than the orphan drug, as
the primary unit, the model better accounts for the fact
that many new orphan drugs are indicated for conditions
in which an approved orphan drug is already available.
The cost impact of having multiple drugs available in one
disease (such as in the treatment of pulmonary arterial
hypertension) is accounted for in the model by estimat-
ing the average penetration rate from diseases with both
single and multiple drugs.
For years 2001 to 2010, the number of orphan diseases
in existence in Europe was determined by reviewing the
European Commission registry of orphan medicines with
marketing approval, and identifying the number of dis-
crete indications [4].
For years 2011 - 2020, the number of new orphan dis-
eases was forecast based upon the following assumptions:
Orphan drug designations rate after 2010 will grow at
10% per annum between 2011 and 2020, reflecting the
average growth rate in designations between 2001 and
2010.
Proportion of drugs with novel indications (as opposed to
drugs being designated for conditions in which at least one
licensed orphan medicine is already approved) was
assumed to be the same as for all orphan drug designations
between 2000 and 2010 - 43% of designated drugs are for
indications in which no other orphan drug is yet licensed.
‘Success rate’ (the proportion of designated orphan
drugs that are given marketing approval) remained
constant at 10.9% of all designations - the level observed
over the last decade. Explanation for this seemingly low
success rate is provided in the Discussion section.
Lag time between designation and approval. Based
upon an analysis of the European Commission registry of
orphan medicines approved for use in Europe between
2000 and 2010, the average lag time between being
granted orphan drug designation and achieving market-
ing authorisation was 4 years. Drugs given orphan drug
designation before 2003 that had not received marketing
approval by the end of 2010 were assumed to be unsuc-
cessful in reaching the market.
Average annual orphan drug cost per orphan disease
The average orphan disease drug cost was estimated for
each year of the lifecycle of an average orphan disease,
starting from the year in which the first orphan medicine
was licensed for use in that indication. This reflects the
fact that the cost of orphan medicines for an orphan dis-
ease will change over time: growing from the year in
which the first drug is launched, as more patients gain
access to treatment, until the point that the first drug
becomes generic, at which point the total cost of orphan
drug treatment in that disease falls.
The orphan drug cost for an average orphan disease was
estimated based upon data on all currently licensed
orphan medicines in Europe. The drug cost was estimated
for each existing orphan disease (for which a designated
orphan medicine was approved) and then an average was
taken across all the diseases.
Individual disease drug costs were calculated using the
following information:
￿ Annual orphan drug costs for each disease were cal-
culated based on the information in the manufac-
turer’s Summary of Product Characteristics (SPC).
Drug dosages reflected the average dose for an adult,
unless the drug was specifically indicated for use in
children. The duration of treatment (chronic, long-
term, short-term, cyclical or episodic) was obtained
from the SPC. Where treatment was administered as
an injected or infused drug, the nearest full vial size
was used.
￿ Prevalence estimates from published data [14] and
EMA regulatory filings were used to quantify the
potential patient population for each disease for
every country included in the analysis.
￿ Availability of orphan medicines across the countries
included in the analysis was estimated based upon a
survey of 10 European countries that found that, of
patients with diseases for which an orphan drug was
licensed, 69% on average had access to the medicine
[15]. This estimate is commensurate with reports that
show that on average only approximately two-thirds of
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access across Europe [15-17]. The percentage of the
total prevalent patient population likely to receive
treatment in each year after the introduction of the
first orphan medicine was estimated based upon his-
torical sales data from a sample of orphan drugs
approved in Europe since 2001. Using estimated preva-
lence as the denominator, the average uptake rate was
seen to be 22% of the prevalent population in 2010. It
should be noted that this factor is based upon the pro-
portion of patients estimated to have the condition
based upon prevalence estimates, rather than those
diagnosed individuals with clinically significant disease
in whom treatment with an orphan drug would be
indicated. Therefore the true ‘uptake rate’ amongst
patients for whom treatment is appropriate is likely to
be much higher than this. However, there is insuffi-
cient published data to estimate the smaller patient
population indicated for each orphan treatment, and
as such total prevalence data was used, with the conse-
quence that the uptake rate figures appears artificially
low. This does not affect the validity of the model, as
the same prevalence-based denominator was used for
both the retrospective analysis of historical data and
the forecast of future orphan cost growth.
To account for the effect of loss of intellectual prop-
erty and marketing exclusivity on orphan medicines,
drug costs were assumed to fall in price by 25% from
the 10
th year after the introduction of the first orphan
medicine in a disease area. This is the average reduction
in price for medicines at the point of loss of patent
observed between 2000-2007 in the European Commis-
sion Pharmaceutical Sector Inquiry Report [18]. The
extent to which this is analogous to the orphan drug
market is explored in the Discussion section.
The year-on-year cost curve for the average orphan dis-
ease was mapped onto the forecast incidence of new
orphan diseases to predict the total budget impact at any
time point. For each year, this total cost was divided by
the estimated total pharmaceutical expenditure of the
Eurozone countries plus UK that was obtained from the
pharmaceutical industry trade body [19]. Estimates of
future total pharmaceutical market value (ex-factory) were
made based upon the growth rates seen over the previous
5 years.
One-way sensitivity analysis was performed on a range of
variables to establish how robust the budget impact esti-
mates were to changes in key parameters and assumptions.
Results
Predicted number of orphan diseases
Figure 1 shows the cumulative number of orphan dis-
eases (defined in this study as a disease in which at least
one designated orphan drug is licensed) observed
between 2002 and 2010, and the forecast number of
cumulative orphan diseases between 2011 and 2020.
The trend is towards a steady increase in the cumulative
number of diseases for which an orphan drug is designated,
averaging just over 5 new diseases per year over the 20
years of the model. The rate of growth in diseases was
more rapid between 2002 - 2010 than 2011 - 2014, reflect-
ing the acceleration in orphan drug designations between
2001 and 2005 and the slowing growth of designations
between 2006 - 2010 (the average lag between designations
and approvals being approximately 4 years). From 2015
forth, the additional increase in orphan diseases is forecast
in line with a designation rate between 2010 - 2015 that is
premised upon designations growing at the average rate
over the period 2001 - 2010 (approximately 10% per year).
Average cost per orphan disease per year
T h ea n n u a lp e rp a t i e n tc o s to fe x i s t i n go r p h a nd r u g s
was seen to vary between €1,251 and €407,631, with the
median cost being €32,242. When combined with the
expected drug penetration rate within the prevalent
patient populations, the average orphan disease drug
cost across the Eurozone and UK was predicted to rise
from €5 m in the year after the first orphan drug was
approved, to €143 m in Year 10, before falling and stea-
dying-off at approximately €110 m per year (Figure 2).
Predicted budget impact of orphan drugs in Eurozone
and UK
The ex-factory value of the total pharmaceutical market
for the countries included in this analysis was estimated
to be €1 4 0b ni n2 0 1 0 ,b a s e du p o nd a t af r o mt h eE u r -
opean Federation of Pharmaceutical Industries and
Associations (EFPIA) [19]. The growth of the total mar-
ket over the next decade was estimated to follow the
same trend identified by EFPIA over the last 5 years -
annual growth of 6.6% [20]. Accordingly, the total phar-
maceutical market in the Eurozone and UK is expected
to grow to €265 bn by 2020. Despite recent price cut-
ting by some European countries, the fundamental
demographic trends in Europe are likely to support con-
tinuing drug market growth within this range [21].
According to the results of the model, the share of the
total European pharmaceutical market represented by
orphan drugs is predicted to increase from 3.3% in 2010 to
a peak of 4.6% in 2016 before steadying-off at a level
between 4% and 5% until 2020 (Figure 3). The flattening
of growth in the budget impact from 2016 onwards does
not mean that the total cost of orphan drugs is expected
to stop growing, but rather that the growth of orphan
d r u ge x p e n d i t u r ei su n l i k e l yt ob es i g n i f i c a n t l yg r e a t e r
than that of the total pharmaceutical market during this
period.
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for which orphan medicines were licensed were for
oncological and haematological conditions, yet these dis-
eases accounted for 57% of the total costs in 2010.
While the average annual cost for oncology treatments
was significantly lower than the average annual cost of
non-oncology treatments (€33,919 and €86,145 respec-
tively), the prevalence of these conditions is on average
higher. For example, the prevalence for Gaucher’sD i s -
ease is 2 per 100,000 population in contrast to a preva-
lence of 32 per 100,000 for B-cell chronic lymphocytic
leukemia.
Deterministic sensitivity analysis demonstrated that
the forecast was not unduly sensitive to changes in any
key parameter (Table 1). In all scenarios the peak-year
budget impact fell within a range of 3% - 6.6%. Changes
to the predicted rate of total pharmaceutical growth
from 6.6% (average over last 5 years) to 3% (the lower
end of current industry analyst projections [21] saw the
peak year budget impact increasing to 5.9%. When the
impact of generic entry was excluded from the analysis,
the peak-year budget impact increased to 5.1%. The
greatest budget impact estimate was associated with
increasing the ‘strike-rate’ parameter (percentage of
designated orphan drugs that go on to receive marketing
approval) to 20% - a rate that is significantly higher than
that observed in either the EU or US since orphan legis-
lation was introduced.
Discussion
T h ef i n d i n g sf r o mt h i sa n a l y s i sd e m o n s t r a t eh o wt h e
budget impact of orphan drugs in Europe has grown
steadily over the 10 years since the introduction of the
orphan drug regulation in 2000, driven primarily by the
approval of new drugs for diseases in which no treat-
ments were previously licensed. The budget impact is
estimated to have grown from 0% in 2000 to 3.3% by
2010. From 2010 to 2016 this growth is predicted to
continue, however the rate of growth is likely to slow
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Figure 2 Average annual drug cost per orphan disease over
the indication lifecycle, for the Eurozone + UK.
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Figure 1 Cumulative orphan diseases: observed (2002 - 2010) and forecast (2011 - 2020).
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o     Predictive estimates from published studies
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Figure 3 Budget impact of orphan drugs as percentage of total pharmaceutical spend (2002 - 2020).
Table 1 Results from one-way sensitivity analysis on key model parameters.
Parameter Value Peak year budget impact as % of total
pharmaceutical spend (year)
1 Lag between orphan drug designation and marketing approval Base 4 yr 4.6% (2016)
Best 6 yr 4.2% (2016)
Worst 2 yr 4.9% (2015)
2 Eurozone + UK pharmaceutical market value in 2010 (ex-factory) Base €140 bn 4.6% (2016)
Best €170 bn 3.8% (2016)
Worst €110 bn 5.8% (2016)
3 Total pharmaceutical market growth per year Base 6.6% 4.6% (2016)
Best 10% 4.0% (2014)
Worst 3% 5.9% (2020)
4 % of products with orphan designation that achieve market
authorisation
Base 10.92% 4.6% (2016)
Best 7% 4.2% (2015)
Worst 20% 6.6% (2016)
5 Growth in new designations per year after 2010 Base 10% 4.6% (2016)
Best 5% 4.6% (2016)
Worst 50% 4.7% (2020)
7 Average cost of orphan disease per year (Yr 1 - Yr 10) Base As per
Figure 2
4.6% (2016)
Best -25% p.a 3.4% (2016)
Worst +25% p.a 5.7% (2016)
8 Drop in drug prices at the point that drugs lose patent protection
or marketing exclusivity
Base 25% 4.6% (2016)
Best 50% 4.2% (2014)
Worst 0% 5.1% (2019)
(’Best’ and ‘worst’ cases are from the perspective of funders of orphan medicines, with ‘best’ representing the lower budget impact and ‘worst’ the higher).
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pharmaceutical market expenditure by 2016. However,
although the budget impact, as a percentage of total
pharmaceutical expenditure, is not expected to grow
beyond 2016, the absolute expenditure on orphan medi-
cines will increase year-on-year, but no faster than the
growth in the greater European pharmaceutical market.
What explains the steadying growth of orphan medi-
cine budget impact over the next decade, forecast in
this analysis? One factor is the loss of marketing exclu-
sivity and patent protection for orphan drugs that were
introduced shortly after the passing of legislation in
2000. For example, major orphan medicines such as
imatinib and bosentan will both lose marketing exclusiv-
ity and patent protection by 2015 [22,23].
A second factor is the low ‘success rate’ for drugs that
have been granted orphan designation. Over the first 10
years since the introduction of European orphan drug
legislation, the success rate for approvals per designation
has averaged 10.9%. While designation rates have grown
steadily over this period, approvals of new treatments have
fluctuated, and in fact fallen from 13 per year in 2007 to 4
in 2010, as shown in Figure 4.
A third reason for the steadying growth of orphan drug
costs is the diminishing penetration rate of new drugs
into prevalent patient populations in the later years after
a drug is first licensed. Of the whole prevalent population
with an orphan disease, only a certain percentage will be
diagnosed and be appropriate for treatment [24]. Those
patients most in need of treatment will be identified
quickly, but the marginal uptake rate diminishes over
time. Access issues - related to pricing and reimburse-
ment restrictions - will also continue to constrain the
patient uptake of new and existing orphan drugs. A
patient access survey conducted by EURORDIS found
that some orphan drugs that have been available on the
market for many years are still not becoming more
widely available over the course of time [15]. Even
excluding the drop in costs associated with loss of mar-
keting exclusivity, this slowing in uptake in the latter part
of the drug-disease lifecycle dampens the overall growth
in orphan drug expenditure.
Combined, these factors mean that the fast cost growth
seen in the past decade is unlikely to continue in the
forthcoming one, with designations and approvals of new
diseases likely to be at a ‘replacement level’ that main-
tains growth in orphan expenditure at a trajectory that is
similar to that of the greater pharmaceutical market.
This analysis has sought to forecast future events - a
process that is inherently subject to uncertainty, assump-
tion and potential bias. The principal form of structural
uncertainty in the model comes from the decision to use
orphan diseases as the primary unit of measurement
rather than individual orphan drugs. By structuring the
model in this fashion, the cost associated with multiple
therapies for a single disease has been incorporated via
the estimated ‘penetration rate’ of potential patients
receiving treatment in each disease. This rate was esti-
mated from existing orphan diseases where both single
and multiple drugs were available.
Parameter uncertainty in the model reflects the nature
of the data sources used. The European Commission
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source for identifying trends in these areas, yet data on
prevalence in individual diseases is relatively weak, and
comparing drug prices across European markets intro-
duces significant complexity. Ex-factory orphan drug
prices were used in the model, but this may not reflect
the true price paid, excluding as it does discounts,
rebates and risk-sharing schemes.
Equally importantly, the potential price erosion when
older orphan drugs lose their patents and marketing exclu-
sivity is difficult to accurately predict. Although there has
been insufficient time to assess this change for orphan
medicines in Europe, in the US, where orphan legislation
was introduced in 1983, the impact of loss of marketing
exclusivity appears to have resulted in significant changes
in price upon the introduction of generic competitors. An
analysis of a sample of 12 drugs that received orphan drug
approval in the US between 1990 and 2000 suggested that
on loss of marketing exclusivity, generic prices were on
average 50% lower than the original drug, with a range of
price reductions from 14% to 95%. Adopting a 25% fall in
price is therefore considered conservative.
I nl i g h to ft h ee c o n o m i cp r e s s u r eo nh e a l t h c a r ea n d
social security budgets, there may also be uncertainty as to
whether the pharmaceutical market growth rate will con-
tinue to be sustained at the historic level of 6.6% per
annum. However, more recent reports on the pharmaceu-
tical industry expect the market to grow 3% - 6% annually
through 2014 [21]. Based on the conservative estimate of a
3% annual growth in the total market, the orphan drug
budget impact would be 5.9% in 2020 (Table 1).
The ‘success rate’ of obtaining marketing approval for
drugs that have been granted orphan designation was
also seen to be an important variable in sensitivity ana-
lysis. Over the first 10 years since the introduction of
the European orphan drug legislation, the success rate
for approvals per designation has averaged 10.9%. This
rate is comparable with the 15.9% success rate observed
in the US over the 28 years since orphan legislation was
introduced in 1983. This relatively low success rate
reflects the broader attrition rate seen in all areas of
pharmaceutical research and development (R&D) and is
less an indication of failure, than a reflection of the
importance of orphan legislation R&D incentives to
drug manufacturers. Companies are incentivised to reg-
ister a treatment for orphan drug designation even if the
probability of success is low (as is often the case in drug
research). Clinical trial da t ai sn o tap r e r e q u i s i t ef o r
orphan drug designation; pre-clinical evidence of effec-
tiveness is sufficient. As manufacturers become more
aware of orphan drug R&D incentives, more drugs are
being designated prior to proof-of-concept, with subse-
quently lower likelihood of drugs succeeding to market-
ing authorisation.
The ‘uptake rate’ used in this analysis is also subject to
uncertainty. The potential patient population for any one
disease - the denominator in the uptake rate - is derived
from published prevalence data, but such data only
reflects the theoretical total population with the disease.
I ti st h e r e f o r en o tat r u er e f l e c t i o no ft h eu p t a k er a t e
within the patient population who are appropriate for
treatment. For example, anagrelide is indicated for essen-
tial thrombocythemia. However, the European license
restricts its use to a patient population who are intolerant
to the established first-line treatment with hydroxycarba-
mide - a much smaller sub-population [25,26]. Similarly,
in Gaucher’s disease prevalence estimates indicate that
5000 patients should exist in a country such as Germany,
yet as of 2010 only 250 (5%) patients were receiving treat-
ment with enzyme replacement therapy there, despite a
product having been available since 1994 [24].
Despite this uncertainty, sensitivity analysis has shown
the model to be robust to changes in key parameter
values and there is relatively little variation in the
expected budget impact of orphan medicines over the
next 10 years, with all results from sensitivity analysis
falling below 6.6% of total pharmaceutical market sales.
In addition, the estimates from the model are supported
by other related literature in this field. Figure 3 overlays the
published estimates from other European researchers on
the results from the study discussed here. As can be seen,
the historical estimates from the model (2001 - 2010) fit
closely with those produced from other sources. The future
estimates of budget impact in this analysis also aligns well
with the forecast for 2013 budget impact from the Belgian
Federal Centre for Healthcare, which also expected the
total budget impact to be approximately 4% at that time.
T h eo n l ye x i s t i n ga n a l y s i st h a ti si n c o n g r u o u sw i t ho u r
findings was that conducted on behalf of the European
Commission, which predicted that the orphan drug budget
impact would be between 6% and 8% by 2010. However
this estimate was made in 2004, based upon the small body
of historical data that was available at that time.
Despite the similarity in findings, the analysis reported
here differs in methodology from those studies reported
previously. It is the first study to attempt to estimate
the budget impact for the region, rather than for specific
markets, which improves the relevance of the results for
policy makers at a European level, but possibly at the
price of lower sensitivity to local variations in orphan
medicine provision. It is also the first study to forecast
forward over a decade, whereas previous studies have
been retrospective [10,11,13] or have forecast forward
over relatively short periods [9,12]. This more ambitious
scope could create greater uncertainty in the analysis,
but at the same time there is more retrospective data
upon which this analysis is based compared with earlier
studies.
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ties in this analysis, further research is required to
inform orphan drug policy moving forward. As more
data becomes available on growth of orphan expendi-
ture, future extrapolations will have greater certainty
and less variance. It will also be valuable to investigate
the likely cost of orphan drugs on a market-by-market
basis, as despite the common assumptions used in this
study, there are likely to be difference between coun-
tries. Further investigation into the composition of
orphan drug cost may also be valuable.
Conclusions
Despite the discussed limitations and the uncertainty
within some parameters, this forecast provides a useful
insight into the likely budget impact of orphan diseases
in Europe in future years, and may aid healthcare policy
makers when planning for the funding of such medicines.
Although orphan drug regulation has led to an increase
in the budget impact of orphan drugs, the cost, as a pro-
portion of total pharmaceutical expenditure, is likely to
plateau between 4% - 5%. Fears of unsustainable cost
escalation should not be used as rationale to review the
orphan drug regulation.
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